Pieris Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Palvella Therapeutics

04/08/2021 13:48

* Pieris Pharmaceuticals Inc  PIRS.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 26 cents per share.
* Revenue fell 70.8% to $3.29 million from a year ago;  analysts
expected $2.08 million. 
* Pieris Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 25 cents​.
* The mean earnings estimate of analysts had fallen by
about 194.4% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Pieris Pharmaceuticals Inc shares had fallen by 5.0% this
quarter and gained 45.6% so far this year.
* The company reported a quarterly loss of $15.5 million.
* Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8.50 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated August 4 at 12:48 p.m.  ​All
figures in US dollars unless otherwise stated